Cleveland Clinic

Cleveland Clinic Laboratories

Technical Update • March 2022

Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. This Technical Update is provided on a monthly basis to notify you of any changes to the tests in our catalog.

Recently changed tests are bolded, and they could include revisions to methodology, reference range, days performed, or CPT code. Deleted tests and new tests are listed separately. For your convenience, tests are listed alphabetically and order codes are provided.

To compare the new information with previous test information, refer to the online Test Directory at clevelandcliniclabs.com. Test information is updated in the online Test Directory on the Effective Date stated in the Technical Update. Please update your database as necessary.

For additional detail, contact Client Services at 216.444.5755 or 800.628.6816, or via email at clientservices@ccf.org.

Test Update Page #	Summary of Changes by Test Name	Order Code	Name Change	New Test	Test Discontinued	Special Information	Specimen Requirement	Component Change(s)	Methodology	Reference Range	Days Performed/Reported	Stability	CPT	Fee
3	25-Hydroxyvitamin D2 and D3											■		
9	Achondroplasia (FGFR3) 2 Mutations				■									
9	AFP – Amniotic Fluid				■									
3	Allergen, Cayenne Pepper										■			
3	Allergen, Cranberry IgE										■			
3	Allergen, Food, Alpha-Gal IgE										■			
3	Allergen, Fungi and Molds, Chaetomium globosum IgE										■			
4	Amitriptyline/Nortriptyline					■	■		■	■	■	■		
9	Anti Enterocyte Antibodies													■
9	Ashkenazi Jewish Diseases				■									
4	Bacterial Vaginosis Amplification												■	
9	Blau Syndrome (NOD2/CARD15 Complete Gene)				■									
9	Cadasil DNA test				■									
9	CNBP Repeat Analysis				■									
9	COL1A1/COL1A2 DNA Sequencing				■									
9	COL3A1 Deletion/Duplication Analysis				■									
9	COL3A1 Gene Sequencing (Blood)				■									
9	Complete HNPP Evaluation				■									
9	Connexin 26				■									
4	Cross-Linked N-telopeptide, Urine					■	■							

Test Update Page #	Summary of Changes by Test Name	Order Code	Name Change	New Test	Test Discontinued	Special Information	Specimen Requirement	Component Change(s)	Methodology	Reference Range	Days Performed/Reported	Stability	CPT	Fee
9	Cystic Fibrosis (CFTR) Sequencing				■									
4	Desipramine					■	■		■	■	■	■		
5	Doxepin/Nordoxepin					■	■		■	■	■	■		
9	Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication with Reflex to Sequencing				■									
9	Dystonia DNA test				■									
9	Familial Hypocalciuric Hypercalcemia Evaluation				■									
9	FBN1 Gene Sequencing Analysis				■									
9	FBN1 Gene Deletion/Duplication Analysis				■									
10	Friedreich's Ataxia DNA Test				■									
10	FSHD DNA Test				■									
10	GLA Gene Testing in Fabry Disease				■									
10	Hemiplegic Migraine Evaluation				■									
10	Huntington's Disease				■									
10	Hydroxylase Gene(CYP21A2), Full Gene Analysis, Blood				■									
5	Imipramine/Desipramine					■	■		■	■	■	■		
10	KCNJ11 (NDM) DNA Sequencing Test				■									
10	Kennedy's Disease DNA Test				■									
6	Leukotriene E4, Urine 24 Hour		■			■	■	■						
10	LHON mtDNA Mutation				■									
10	Medium Chain Acyl-CoA Dehydrogenase, Tier 1, Targeted				■									
10	MFN2 DNA Sequencing Test				■									
8	Miscellaneous Send Out Test			■										
10	Miscellaneous Send Out Test 13				■									
10	Miscellaneous Send Out Test 14				■									
10	Miscellaneous Send Out Test 15				■									
10	Miscellaneous Send Out Test 16				■									
8	Miscellaneous Send Out Test 2			■										
8	Miscellaneous Send Out Test 3			■										
10	Monogenic Diabetes (MODY) Evaluation				■									
10	Muckle-Wells Syndrome				■									
10	Multifocal Neuropathy Evaluation				■									
10	MVK Testing in Hyper-IgD Syndrome				■									
10	Neurofibromatosis Type 2 DNA				■									
6	Neuron Specific Enolase, CSF									■				
6	Nortriptyline					■	■		■	■	■	■		
10	OPMD Repeat Expansion Test				■									
10	Pancreatitis Panel				■									
10	PAX6 Gene Analysis				■									

Test Update Page #	Summary of Changes by Test Name	Order Code	Name Change	New Test	Test Discontinued	Special Information	Specimen Requirement	Component Change(s)	Methodology	Reference Range	Days Performed/Reported	Stability	CPT	Fee
6, 9	Plasminogen Activator Inhibitor Antigen										■	■	■	■
10	PMP22 DNA Sequencing Test					■								
10	PMP22 Duplication/Deletion DNA					■								
10	PTEN Gene Analysis					■								
11	SCA1 DNA test					■								
11	SCA2 Expansion Analysis					■								
11	SCA3 DNA Test					■								
11	SCA6 DNA Test					■								
11	SCA7 DNA Test					■								
7	Syphilis Total with reflex						■			■		■		
11	TRAPS/Familial Hibernian Fever					■								
11	TTR Gene, Full Gene Analysis					■								
7	Vitamin B5 (Pantothenic Acid) Bioassay						■							
11	von Willebrand Type 2N Sequence Analysis					■								
8	VWF GPIbM Activity			■										

Test Changes

Test Name	Order Code	Change	Effective Date
25-Hydroxyvitamin D2 and D3	D2D3	**Specimen Requirement:** 1 mL plasma from EDTA (Lavender) tube; Minimum 0.5 mL; Refrigerated; **Centrifuge and transfer plasma/serum to a CCL tube and refrigerate.** *OR* 1 mL serum from No additive (Red) tube; Minimum 0.5 mL; Refrigerated; **Centrifuge and transfer plasma/serum to a CCL tube and refrigerate.** ***OR*** 1 mL plasma from EDTA (Navy Blue) tube; Minimum 0.5 mL; **Centrifuge and transfer plasma/serum to a CCL tube and refrigerate.** **Stability:** Ambient: **7 days** Refrigerated: **21 days** Frozen: **30 days**	effective immediately
Allergen, Cayenne Pepper	CAYENN	**Reported:** 2–**4** days	3/31/22
Allergen, Cranberry IgE	CRANBY	**Reported:** 2–**4** days	3/31/22
Allergen, Food, Alpha-Gal IgE	GALIGE	**Reported:** 2–**4** days	3/31/22
Allergen, Fungi and Molds, Chaetomium globosum IgE	CHAETG	**Reported:** 2–**4** days	3/31/22

Test Changes (Cont.)

Test Name	Order Code	Change	Effective Date
Amitriptyline/ Nortriptyline	AMINOR	**Special Information: Collect immediately prior to next dose. Do not collect in a gel separator tube. This test is New York DOH approved.** **Clinical Information: This test is useful for optimizing drug therapy and monitoring patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause anticholinergic effects, cardiac abnormalities and seizures.** **Specimen Requirement: 1 ml serum from No additive (Red) tube; Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate serum from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** *OR* **1 ml** plasma from EDTA (Lavender) tube; **Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate plasma from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** **Stability:** Ambient: 5 days Refrigerated: 2 weeks Frozen: **6** months **Methodology: Quantitative Liquid Chromatography–Tandem Mass Spectrometry** **Reference Range:** Amitriptyline (AMI): Not Established Nortriptyline alone (NORTRI): **Therapeutic Range: 50–150 ng/mL** Amitriptyline and Nortriptyline (TOTAMI): **Therapeutic Range: 95–250 ng/mL** **Toxic Level: Greater than 500 ng/mL** **Days Performed: Mon, Wed, Fri** **Reported: 2–6** days	4/19/22
Bacterial Vaginosis Amplification	BVAMP	**CPT: 81513**	effective immediately
Cross-Linked N-telopeptide, Urine	UNTX2	**Special Information: Second morning fasting urine is required.** **Specimen Requirement:** 5 mL **second-morning void urine** in a clean container; Minimum 2 mL; Refrigerated; **Fasting urine is required**	3/29/22
Desipramine	DESIPR	**Special Information: Collect immediately prior to next dose. Do not collect in a gel separator tube. This test is New York DOH approved.** **Clinical Information: This test is useful for optimizing drug therapy and monitoring patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause anticholinergic effects, drowsiness and cardiac abnormalities.** **Specimen Requirement: 1 ml serum from No additive (Red) tube; Minimum 0.5 mL;** Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate serum from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube. *OR* 1 ml** plasma from EDTA (Lavender) tube; **Minimum 0.5 mL;** Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate plasma from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** **Stability:** Ambient: 5 days Refrigerated: 2 weeks Frozen: **6** months **Methodology: Quantitative Liquid Chromatography–Tandem Mass Spectrometry** **Reference Range:** **Therapeutic Range: 100–300 ng/mL** **Toxic Level: Greater than 500 ng/mL** **Reported: 2–6** days	4/19/22

Test Changes (Cont.)

Test Name	Order Code	Change	Effective Date
Doxepin/Nordoxepin	DOXEPN	**Special Information: Collect immediately prior to next dose. Do not collect in a gel separator tube. This test is New York DOH approved.** **Clinical Information: This test is useful for optimizing drug therapy and monitoring patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause anticholinergic effects and cardiac abnormalities.** **Specimen Requirement: 1 ml serum from No additive (Red) tube; Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate serum from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** *OR* **1 ml** plasma from EDTA (Lavender) tube; **Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate plasma from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** **Stability:** Ambient: 5 days Refrigerated: 2 weeks Frozen: **6** months **Methodology: Quantitative Liquid Chromatography–Tandem Mass Spectrometry** **Reference Range:** Doxepin (DOX): Not Established Nordoxepin (NORDOX): Not Established Doxepin/Nordoxepin (TOTDOX): **Therapeutic Range: 100–300 ng/mL** **Toxic Level: Greater than 500 ng/mL** **Reported: 2–6** days	4/19/22
Imipramine/ Desipramine	IMIDES	**Special Information: Collect immediately prior to next dose. Do not collect in a gel separator tube. This test is New York DOH approved.** **Clinical Information: This test is useful for optimizing drug therapy and monitoring patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause anticholinergic effects, drowsiness and cardiac abnormalities.** **Specimen Requirement: 1 ml serum from No additive (Red) tube; Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate serum from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** *OR* **1 ml** plasma from EDTA (Lavender) tube; **Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate plasma from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** **Stability:** Ambient: 5 days Refrigerated: 2 weeks Frozen: **6** months **Methodology: Quantitative Liquid Chromatography–Tandem Mass Spectrometry** **Reference Range:** Imipramine (IMIPRA): Not Established Desipramine (DESIP): **Not Established** Total Imipramine and Desipramine (TOTIMI): **Therapeutic Range: 150–300 ng/mL** **Toxic Level: Greater than 500 ng/mL** **Reported: 2–6** days	4/19/22

Test Changes (Cont.)

Test Name	Order Code	Change	Effective Date
Leukotriene E4, Urine 24 Hour	ULTE4	**For interface clients only: Test build may need to be modified** **Test Name:** Previously Leukotriene E4, Urine **Special Information: 24 hour volume is required. No preservatives preferred. This test is New York DOH approved.** **Specimen Requirement: 5** mL urine from 24-hour (well-mixed) clean container; **Minimum 2 mL**; Refrigerate during collection; 24 hour volume is required. No preservatives preferred **Note:** *Random urine is no longer acceptable* **Reference Range:** Leukotriene E4, Ur (ULE): Less than or equal to 104 pg/mg creatinine **Creatinine, 24 Hr, Ur (CRT24):** **Male: 18–999 Years: 930–2955 mg/24 hours** **Female: 18–999 Years: 603–1783 mg/24 hours**	3/8/22
Neuron Specific Enolase, CSF	CNSE	**Reference Range:** Less than or equal to **21.5** ng/mL	effective immediately
Nortriptyline	NORTRP	**Special Information: Collect immediately prior to next dose. Do not collect in a gel separator tube. This test is New York DOH approved.** **Clinical Information: This test is useful for optimizing drug therapy and monitoring patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause anticholinergic effects, cardiac abnormalities and seizures.** **Specimen Requirement: 1 ml serum from No additive (Red) tube**; **Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate serum from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** *OR* **1 ml** plasma from EDTA (Lavender) tube; **Minimum 0.5 mL**; Refrigerated; Collect immediately prior to next dose. **Do not use gel separator tubes. Separate plasma from cells ASAP or within 2 hours of collection and transfer into a standard aliquot tube.** **Stability:** Ambient: 5 days Refrigerated: 2 weeks Frozen: **6** months **Methodology: Quantitative Liquid Chromatography–Tandem Mass Spectrometry** **Reference Range:** Nortriptyline (NORTRP): **Therapeutic Range: 50–150 ng/mL** **Toxic Level: Greater than 500 ng/mL** **Reported: 2–6** days	4/19/22
Plasminogen Activator Inhibitor Antigen	PAI1M	**Stability:** Frozen: **1 year** **Reference Range: 4–43 ng/mL** **Days Performed: Fri** **Reported: 5–9 days** **CPT: 85415** **Price: $220**	effective immediately

Test Changes (Cont.)

Test Name	Order Code	Change	Effective Date
Syphilis Total with reflex	SYPHTX	**Special Information: Results in samples from immunosuppressed patients or from patients with disorders leading to immunosuppression should be interpreted with caution.** **Clinical Limitation:** Not intended for use in the screening of blood, plasma **or tissue donors. Performance has not been established for the use of cadaveric specimens or the use of body fluids (other than serum). Avoid specimens with the following conditions: heat-inactivated, grossly hemolyzed (> 500 mg/dL hemoglobin), grossly lipemic, or obvious microbial contamination.** **Clinical Information: A nonreactive result does not totally exclude a recent, within the past 2–3 weeks, Treponema pallidum infection. Detection of treponemal antibodie may indicate recent, past, or successfully treated syphilis infections and therefore cannot be used to differentiate between active and cured cases.** **Stability:** Ambient: **3 days** Refrigerated: 7 days Frozen: **30 days** **Methodology: Chemiluminescent Microparticle Immunoassay (CMIA)** **Days Performed:** Mon–Sat **7:00 am–11:00 pm**	effective immediately
Vitamin B5 (Pantothenic Acid) Bioassay	VITB5	**Special Information:** Critical: MUST protect from light. Specimens not protected from light will be rejected. Grossly hemolyzed or lipemic specimens are unacceptable. **Note**: *New York testing comment removed*	effective immediately

New Tests

Test Name	Order Code	Change	Effective Date
Miscellaneous Send Out Test	MISC1	Replacement order code for current WILD13, WILD14, WILD15 and WILD16 tests. This order code will be used only for tests not specifically defined at Cleveland Clinic.	effective immediately
Miscellaneous Send Out Test 2	MISC2	Replacement order code for current WILD13, WILD14, WILD15 and WILD16 tests. This order code will be used only for tests not specifically defined at Cleveland Clinic.	effective immediately
Miscellaneous Send Out Test 3	MISC3	Replacement order code for current WILD13, WILD14, WILD15 and WILD16 tests. This order code will be used only for tests not specifically defined at Cleveland Clinic.	effective immediately
VWF GPIbM Activity	VGPIBM	**Includes:** VWF GP1bM Activity Interpretation and Comments **Special Information:** This test is New York DOH approved. **Clinical Limitation:** VWF is an acute phase reactant. Levels will be elevated postoperatively, with inflammation, stress, physical activity, pregnancy, estrogen therapy and hyperthyroidism. VWF levels may be artifactually reduced as a consequence of improper sample handling. VWF activity assays should be correlated with other VWF assays and with patient clinical history to support an appropriate diagnosis. For some cases of type 2B VWD, VWF GPIbM Activity will report a higher activity level than VWF Ristocetin Cofactor Activity. Therefore, VWF GPIbM Activity results should be interpreted cautiously when monitoring perioperative therapy in patients with type 2B VWD. **Clinical Information:** von Willebrand disease (VWD) is a bleeding disorder characterized by either quantitative or qualitative defects of von Willebrand factor (VWF). Accurate measurement of VWF activity by assessment of its interaction with platelets is an essential component of the evaluation of a patient where there is concern for von Willebrand disease. While the VWF Ristocetin Cofactor Activity (VWF: RCo) assay has been used for decades to measure VWF platelet binding activity, the assay's imprecision and poor sensitivity are significant drawbacks. The VWF GPIbM Activity assay measures binding of VWF to mutant GPIb□ without the need for ristocetin and is well correlated with the VWF:RCo assay. The VWF GPIbM Activity assay demonstrates superior precision and sensitivity compared with the VWF ristocetin cofactor assay. Furthermore, it is not subject to falsely low values seen in individuals who possess the common p.D1472H polymorphism or the rare p.P1467S variant, both of which confound the accurate diagnosis of von Willebrand disease. Since discrepancies between VWF activity and VWF antigen suggest variant VWD, accurate measurement of VWF activity via the VWF GPIbM Activity assay offers an advance in the evaluation of patients where there is concern for VWD. **Specimen Requirement:** 0.5 mL plasma from Sodium citrate (Light Blue) tube; Minimum 0.3 mL; Frozen **Stability:** Ambient: 4 hours Refrigerated: Unacceptable Frozen: 2 weeks **Methodology:** Enzyme-Linked Immunosorbent Assay (ELISA) **Days Performed:** Varies **Reported:** 8–9 days **CPT:** 85397	4/12/22

Fee Increases

Test Name	Order Code	List Fee	CPT Code	Effective Date
Anti Enterocyte Antibodies	ENTERO	$750.00		effective immediately

Fee Reductions

Test Name	Order Code	List Fee	CPT Code	Effective Date
Plasminogen Activator Inhibitor Antigen	PAI1M	$220.00	85415	effective immediately

Discontinued Tests

Test Name	Order Code	Test Information	Effective Date
Achondroplasia (FGFR3) 2 Mutations	ADPLAS	Test will no longer be orderable. For lab use only.	4/21/22
AFP – Amniotic Fluid	FAFPAM	Test will no longer be orderable.	3/31/22
Ashkenazi Jewish Diseases	AJPWO	Test will no longer be orderable. For lab use only.	4/21/22
Blau Syndrome (NOD2/CARD15 Complete Gene)	BLAU	Test will no longer be orderable. For lab use only.	4/21/22
Cadasil DNA test	CADASL	Test will no longer be orderable. For lab use only.	4/21/22
CNBP Repeat Analysis	DM2DNA	Test will no longer be orderable. For lab use only.	4/21/22
COL1A1/COL1A2 DNA Sequencing	COLA12	Test will no longer be orderable. For lab use only.	4/21/22
COL3A1 Deletion/ Duplication Analysis	COL3DD	Test will no longer be orderable. For lab use only.	4/21/22
COL3A1 Gene Sequencing (Blood)	COL3	Test will no longer be orderable. For lab use only.	4/21/22
Complete HNPP Evaluation	HNPP	Test will no longer be orderable. For lab use only.	4/21/22
Connexin 26	CON26	Test will no longer be orderable. For lab use only.	4/21/22
Cystic Fibrosis (CFTR) Sequencing	CFSEQ	Test will no longer be orderable. For lab use only.	4/21/22
Duchenne/Becker Muscular Dystrophy (DMD) Deletion/ Duplication with Reflex to Sequencing	DBMDYS	Test will no longer be orderable. For lab use only.	4/21/22
Dystonia DNA test	DYSTON	Test will no longer be orderable. For lab use only.	4/21/22
Familial Hypocalciuric Hypercalcemia Evaluation	FHHE	Test will no longer be orderable. For lab use only.	4/21/22
FBN1 Gene Sequencing Analysis	FBN1	Test will no longer be orderable. For lab use only.	4/21/22
FBN1 Gene Deletion/ Duplication Analysis	FBN1DD	Test will no longer be orderable. For lab use only.	4/21/22

Discontinued Tests (Cont.)

Test Name	Order Code	Test Information	Effective Date
Friedreich's Ataxia DNA Test	FRIED	Test will no longer be orderable. For lab use only.	4/21/22
FSHD DNA Test	FSHDNA	Test will no longer be orderable. For lab use only.	4/21/22
GLA Gene Testing in Fabry Disease	FABRY	Test will no longer be orderable. For lab use only.	4/21/22
Hemiplegic Migraine Evaluation	HEMMIG	Test will no longer be orderable. For lab use only.	4/21/22
Huntington's Disease	HUNTDI	Test will no longer be orderable. For lab use only.	4/21/22
Hydroxylase Gene(CYP21A2), Full Gene Analysis, Blood	21GENA	Test will no longer be orderable. For lab use only.	4/21/22
KCNJ11 (NDM) DNA Sequencing Test	KCNJ	Test will no longer be orderable. For lab use only.	4/21/22
Kennedy's Disease DNA Test	KENEDY	Test will no longer be orderable. For lab use only.	4/21/22
LHON mtDNA Mutation	LHON	Test will no longer be orderable. For lab use only.	4/21/22
Medium Chain Acyl-CoA Dehydrogenase, Tier 1, Targeted	MCADD	Test will no longer be orderable. For lab use only.	4/21/22
MFN2 DNA Sequencing Test	MFN2	Test will no longer be orderable. For lab use only.	4/21/22
Miscellaneous Send Out Test 13	WILD13	Test will no longer be orderable. Recommendeded replacement tests are Miscellaneous Send Out Test (MISC1), Miscellaneous Send Out Test 2 (MISC2) or Miscellaneous Send Out Test 3 (MISC3)	effective immediately
Miscellaneous Send Out Test 14	WILD14	Test will no longer be orderable. Recommendeded replacement tests are Miscellaneous Send Out Test (MISC1), Miscellaneous Send Out Test 2 (MISC2) or Miscellaneous Send Out Test 3 (MISC3)	effective immediately
Miscellaneous Send Out Test 15	WILD15	Test will no longer be orderable. Recommendeded replacement tests are Miscellaneous Send Out Test (MISC1), Miscellaneous Send Out Test 2 (MISC2) or Miscellaneous Send Out Test 3 (MISC3)	effective immediately
Miscellaneous Send Out Test 16	WILD16	Test will no longer be orderable. Recommendeded replacement tests are Miscellaneous Send Out Test (MISC1), Miscellaneous Send Out Test 2 (MISC2) or Miscellaneous Send Out Test 3 (MISC3)	effective immediately
Monogenic Diabetes (MODY) Evaluation	MODY	Test will no longer be orderable. For lab use only.	4/21/22
Muckle-Wells Syndrome	MUCKLE	Test will no longer be orderable. For lab use only.	4/21/22
Multifocal Neuropathy Evaluation	MULNEU	Test will no longer be orderable. For lab use only.	4/21/22
MVK Testing in Hyper-IgD Syndrome	MVK	Test will no longer be orderable. For lab use only.	4/21/22
Neurofibromatosis Type 2 DNA	NEUFIB	Test will no longer be orderable. For lab use only.	4/21/22
OPMD Repeat Expansion Test	OPMD	Test will no longer be orderable. For lab use only.	4/21/22
Pancreatitis Panel	PANCPL	Test will no longer be orderable. For lab use only.	4/21/22
PAX6 Gene Analysis	PAX6	Test will no longer be orderable. For lab use only.	4/21/22
PMP22 DNA Sequencing Test	PMP22	Test will no longer be orderable. For lab use only.	4/21/22
PMP22 Duplication/ Deletion DNA	PMPDEL	Test will no longer be orderable. For lab use only.	4/21/22
PTEN Gene Analysis	PTEN	Test will no longer be orderable. For lab use only.	4/21/22

Discontinued Tests (Cont.)

Test Name	Order Code	Test Information	Effective Date
SCA1 DNA test	SCA1	Test will no longer be orderable. For lab use only.	4/21/22
SCA2 Expansion Analysis	SCA2	Test will no longer be orderable. For lab use only.	4/21/22
SCA3 DNA Test	SCA3	Test will no longer be orderable. For lab use only.	4/21/22
SCA6 DNA Test	SCA6	Test will no longer be orderable. For lab use only.	4/21/22
SCA7 DNA Test	SCA7	Test will no longer be orderable. For lab use only.	4/21/22
TRAPS/Familial Hibernian Fever	TRAPS	Test will no longer be orderable. For lab use only.	4/21/22
TTR Gene, Full Gene Analysis	TTRGEN	Test will no longer be orderable. For lab use only.	4/21/22
von Willebrand Type 2N Sequence Analysis	TYPE2N	Test will no longer be orderable. For lab use only.	4/21/22